Natural Does Not Mean Safe: Knowing the Potential Cardiovascular Risks for Younger Adults Using Cannabis
Presenter: Robert Lee Page II, PharmD, MSPH
Cost: $27
Description
Cannabis use, particularly daily use, is associated with increased cardiovascular risks, including a higher chance of heart attack, stroke, and coronary artery disease. These risks are elevated even in individuals without pre-existing heart conditions. Furthermore, cannabis use can lead to heart rhythm abnormalities and negatively impact vascular function. These major cardiovascular adverse events, while typically occurring in older adults, are now emerging in younger adults exposed to cannabis. This webinar will explore the potential mechanisms and risks surrounding cannabis use in this highly vulnerable population.
Learning Objectives
- Delineate the potential pathological mechanisms surrounding cannabis use and the development of cardiovascular disease within young adults.
- Highlight the current evidence and risk factors surrounding the development of early atherosclerotic cardiovascular disease, stroke, and arrhythmias in younger adults using cannabis.
- Review the recommendations regarding cannabis from the American Heart Association 2020 Clinical Science Statement
- Develop potential strategies to communicate these cardiovascular risks to younger adults.
Speaker Bio
Robert Lee Page II, PharmD, MSPH is a Professor in the Departments of Clinical Pharmacy, Medicine, and Physical/Rehabilitative Medicine at the University of Colorado Denver, Schools of Pharmacy and Medicine (Aurora), and the clinical pharmacy specialist for the Division of Cardiology Section of Advanced Heart Failure and Heart Transplantation. He is also the Clinical Director for the Colorado Evidenced Based Drug Utilization Program though the Colorado Department of Health Financing and Policy, which manages the state Medicaid benefit.
Dr. Page received his bachelors of science degree in biology and chemistry from Furman University (Greenville, SC); bachelor’s of science in pharmacy and Pharm.D. degrees from the Medical University of South Carolina (MUSC; Charleston); Masters of Science in Public Health with an epidemiology focus from the University of Colorado School of Medicine (Denver); and specialty residency in pharmacotherapy with a focus in cardiology from MUSC. He is a board-certified pharmacotherapy specialist with added qualifications in cardiology, and a Fellow of the following organizations: the Heart Failure Society of America, the American College of Clinical Pharmacy, the American Heart Association (Council on Clinical Cardiology), the American Society of Consultant Pharmacists, and the American Society of Health-System Pharmacists.
Dr Page has served and chaired on numerous AHA, HFSA, and ACC committees, was the first chair of the Clinical Pharmacology Subcommittee of the Council on Clinical Cardiology. He has been an external reviewer for several ACCF/AHA cardiovascular management guidelines. Within the AHA, he has served on numerous leadership positions within Clinical Cardiology and QCOR councils, chaired two clinical science statements, has been a writing member on a total of five, and has served as a voice for the AHA on several health policy related issues at the FDA and NIH, as well as, state and national media outlets regarding the cannabis use, smokeless nicotine products, drug shortages, and use of complementary and alternative medicines in patients with cardiovascular disease.
Dr. Page has 30 years of clinical expertise in the management of patients with heart failure in both the outpatient and inpatient setting. He has published over 250 peer reviewed manuscripts, abstracts, and book chapters in the management of patients with cardiovascular disease.
Questions?
Email Founder & CEO, Laura Stack,